Abstract
These basic concepts underpin translational addiction-related research that can help the multitude of victims of genetically induced RDS become the recipients of better therapeutic relapse-preventive tactics. Finally, as neuroscientists and psychiatrists, working in the “addiction space” we encourage the global scientific community to take heed and reconsider the current utilization of dopaminergic blockade and instead adopt the goal of regaining dopamine homeostasis. Optimistically, early predisposition diagnosis through genetic testing; including pharmacogenetic and pharmacogenomic monitoring, with appropriate urine drug screening, and treatment with pro-dopamine regulators could conceivably reduce stress, craving, and relapse and enhance well-being in the recovery community. Following required basic and clinically directed research, the notion of genetically guided therapy may become a front-line technology with the potential to overcome, in part, the current heightened rates of substance abuse.
Highlights
Following almost three decades of genetic-based research related to identifying and characterizing addiction-related Reward Deficiency Syndrome (RDS), a paradigm shift is proposed in the prevention and treatment of all types of addictive behaviors
Studies on the MOR variants are primarily related to substance use disorder: alcohol, food, opiate/opioid, and nicotine dependence; and RDS behaviors: overeating, inability to cope with stress, and PTSD
Smith in the late 60’s “love needs care” [129]?. These basic concepts underpin translational addiction-related research that can help the multitude of victims of genetically induced RDS become the recipients of better therapeutic relapsepreventive tactics
Summary
Following almost three decades of genetic-based research related to identifying and characterizing addiction-related Reward Deficiency Syndrome (RDS), a paradigm shift is proposed in the prevention and treatment of all types of addictive behaviors. Some examples of functional research and studies that associated RDS behaviors with the risk alleles of the genes and second messengers that comprise the GARS test follow. Peer-reviewed studies involving the DRD1 gene show that carriers have an increased risk for many substance abuse and novelty seeking (NS) reward deficiency behaviors.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
